ArrowMark Colorado Holdings’s Vaxcyte PCVX Stock Holding History

ArrowMark Colorado Holdings’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-40,000	Closed	-$2.32M	–	314
2026 Q1	$2.32M	Hold	40,000	–	–	0.06%	215
2025 Q4	$1.85M	Hold	40,000	–	–	0.04%	247
2025 Q3	$1.44M	Hold	40,000	–	–	0.03%	243
2025 Q2	$1.3M	Hold	40,000	–	–	0.02%	246
2025 Q1	$1.51M	Hold	40,000	–	–	0.02%	236
2024 Q4	$3.27M	Hold	40,000	–	–	0.04%	220
2024 Q3	$4.57M	Hold	40,000	–	–	0.06%	199
2024 Q2	$3.02M	Hold	40,000	–	–	0.04%	230
2024 Q1	$2.73M	Buy	+40,000	New	+$2.77M	0.03%	233

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

ArrowMark Colorado Holdings's PCVX Position: Q2 2026 in Review

ArrowMark Colorado Holdings sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 40,000 shares — an estimated $2.32M sold.

ArrowMark Colorado Holdings first reported a position in PCVX in Q1 2024 and held it in 9 quarters. The position peaked at $4.57M in Q3 2024. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

ArrowMark Colorado Holdings reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
ArrowMark Colorado Holdings sold 40,000 Vaxcyte shares in Q2 2026, an estimated $2.32M.
ArrowMark Colorado Holdings first reported a position in Vaxcyte in Q1 2024 and held it in 9 quarters.
ArrowMark Colorado Holdings's Vaxcyte position peaked at $4.57M in Q3 2024.
332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.